Advanced Viral Research Files an Amendment to its Existing IND to Include Topical and Intralesional Therapy (Business Wire via Yahoo! Finance)
YONKERS, N.Y.----Advanced Viral Research Corp. a bio-pharmaceutical company, announced today that it has filed an amendment with the FDA to its existing IND to expand the use of its product, AVR118 to include topical and intralesional therapy.

DOR BioPharma Reports Advances in Stabilization and Optimization of RiVax(TM) Vaccine Formulation (SYS-CON Media)
DOR BioPharma, Inc. (OTCBB: DORB) ('DOR' or 'theCompany') announced today that the Company has made advancements in thelong-term stability and optimization of the formulation of RiVax(TM), avaccine that contains a recombinant subunit of the A chain of ricin toxinand has been shown to induce ricin neutralizing antibodies in humans andanimals. An article characterizing the conditions for

Spectrum to receive $5 mn milestone from Par Pharma for sumatriptan injection (PharmaBiz)
Spectrum Pharmaceuticals, Inc. announced that it will receive a $5 million milestone payment under its agreement with Par Pharmaceutical Companies, Inc. for sumatriptan injection. Sumatriptan injection is a prescription medicine for the acute treatment of migraine attacks.